98488-10-9

Basic information

• Product Name: 2,5-DIMETHYLPYRAZOLO(1,5-A)PYRIMIDIN-7-ONE
• Synonyms: 2,5-DIMETHYL-4,7-DIHYDROPYRAZOLO[1,5-A]PYRIMIDIN-7-ONE;2,5-DIMETHYLPYRAZOLO(1,5-A)PYRIMIDIN-7-ONE;2,5-Dimethylpyrazol(1,5-a)pyrimidin-7-one;2,5-DIMETHYLPYRAZOLO[1,5-A]PYRIMIDIN-7(4H)-ONE;2,7-diMethyl-1,4-dihydropyrazolo[1,5-a]pyriMidin-4-one
• CAS NO: 98488-10-9
• Molecular Formula: C8H9N3O
• Molecular Weight: 163.18
• Mol File: 98488-10-9.mol
• Article Data: 6

Chemical Properties

• Melting Point: 252 °C
• Boiling Point: 266.3°Cat760mmHg
• Flash Point: 114.9°C
• Appearance: /
• Density: 1.35g/cm³
• Vapor Pressure: 0.001mmHg at 25°C
• Refractive Index: 1.671
• CAS DataBase Reference: 2,5-DIMETHYLPYRAZOLO(1,5-A)PYRIMIDIN-7-ONE(CAS DataBase Reference)
• NIST Chemistry Reference: 2,5-DIMETHYLPYRAZOLO(1,5-A)PYRIMIDIN-7-ONE(98488-10-9)
• EPA Substance Registry System: 2,5-DIMETHYLPYRAZOLO(1,5-A)PYRIMIDIN-7-ONE(98488-10-9)

Safety Data

• Safety Statements: 22-24/25
• Hazardous Substances Data: 98488-10-9(Hazardous Substances Data)

Usage

General Description

2,5-DIMETHYLPYRAZOLO(1,5-A)PYRIMIDIN-7-ONE is a chemical compound with the molecular formula C7H8N4O. It is a heterocyclic compound with a pyrazolo[1,5-a]pyrimidine ring system, and it is also known as 7-Methyl-2,5-dimethylpyrazolo[1,5-a]pyrimidin-7-one. It is used in the pharmaceutical industry as a building block for the synthesis of various biologically active compounds. It is also a potential drug candidate for the treatment of cancer, inflammation, and other diseases. Additionally, it has been studied for its antimicrobial, antiviral, and antifungal properties. Overall, 2,5-DIMETHYLPYRAZOLO(1,5-A)PYRIMIDIN-7-ONE is a versatile compound with potential applications in medicine and agrochemicals.

InChI:InChI=1/C8H9N3O/c1-5-4-8(12)11-7(9-5)3-6(2)10-11/h3-4,9H,1-2H3

Upstream product

• 31230-17-8 3-methyl-5-aminopyrazole 
• 141-97-9 ethyl acetoacetate 
• 31230-17-8 3-amino-5-methylpyrazole 
• 105-45-3 acetoacetic acid methyl ester 

Downstream Products

• 136549-13-8 7-chloro-2,5-dimethyl-pyrazolo[1,5-a]pyrimidine 
• 1031639-13-0 C₁₄H₁₄N₄ 

Relevant articles and documents

Comparative study between the anti-P. falciparum activity of triazolopyrimidine, pyrazolopyrimidine and quinoline derivatives and the identification of new PfDHODH inhibitors

In this work, we designed and synthesized 35 new triazolopyrimidine, pyrazolopyrimidine and quinoline derivatives as P. falciparum inhibitors (3D7 strain). Thirty compounds exhibited anti-P. falciparum activity, with IC50 values ranging from 0.030 to 9.1 μM. The [1,2,4]triazolo[1,5-a]pyrimidine derivatives were more potent than the pyrazolo[1,5-a]pyrimidine and quinoline analogues. Compounds 20, 21, 23 and 24 were the most potent inhibitors, with IC50 values in the range of 0.030–0.086 μM and were equipotent to chloroquine. In addition, the compounds were selective, showing no cytotoxic activity against the human hepatoma cell line HepG2. All [1,2,4]triazolo[1,5-a]pyrimidine derivatives inhibited PfDHODH activity in the low micromolar to low nanomolar range (IC50 values of 0.08–1.3 μM) and did not show significant inhibition against the HsDHODH homologue (0–30% at 50 μM). Molecular docking studies indicated the binding mode of [1,2,4]triazolo[1,5-a]pyrimidine derivatives to PfDHODH, and the highest interaction affinities for the PfDHODH enzyme were in agreement with the in vitro experimental evaluation. Thus, the most active compounds against P. falciparum parasites 20 (R = CF3, R1 = F; IC50 = 0.086 μM), 21 (R = CF3; R1 = CH3; IC50 = 0.032 μM), 23, (R = CF3, R1 = CF3; IC50 = 0.030 μM) and 24 (R = CF3, 2-naphthyl; IC50 = 0.050 μM) and the most active inhibitor against PfDHODH 19 (R = CF3, R1 = Cl; IC50 = 0.08 μM - PfDHODH) stood out as new lead compounds for antimalarial drug discovery. Their potent in vitro activity against P. falciparum and the selective inhibition of the PfDHODH enzyme strongly suggest that this is the mechanism of action underlying this series of new [1,2,4]triazolo[1,5-a]pyrimidine derivatives.

Aminopyrazolo[1,5-a]pyrimidines as potential inhibitors of Mycobacterium tuberculosis: Structure activity relationships and ADME characterization

Whole-cell high-throughput screening of a diverse SoftFocus library against Mycobacterium tuberculosis (Mtb) generated a novel aminopyrazolo[1,5-a]pyrimidine hit series. The synthesis and structure activity relationship studies identified compounds with p

THIAZOLE PYRAZOLOPYRIMIDINES AS CRF1 RECEPTOR ANTAGONISTS

The present invention relates to compounds of Formula (I), pharmaceutical compositions thereof, and use thereof as corticotropin releasing factor 1 (CRF1) receptor antagonists in the treatment of psychiatric and neuroendocrine disorders, neurological dise